Neurobiology of Diabetic Neuropathy
- 1st Edition, Volume 50 - August 5, 2002
- Latest edition
- Editors: David Tomlinson, Ronald J. Bradley, R. Adron Harris, Peter Jenner
- Language: English
This volume of International Review of Neurobiology defines primary biochemical causation of diabetic complications, identifies cellular glucose transducers, balancing roles of pro… Read more
Purchase options
This volume of International Review of Neurobiology defines primary biochemical causation of diabetic complications, identifies cellular glucose transducers, balancing roles of protein kinase C and MAP kinases, and sets in context the role of apoptosis and the interactive roles of neurons and Schwann cells. It also defines the cell biology of autonomic neuropathy, considers the balanced needs of science, clinical practice, and economics in clinical trial design, provides the definitive evaluation of aldose reductase inhibitors, and explains the failure of nerve growth factor.
One of the most successful series in the field of neuroscience continues its standard of excellence with this newest edition. Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists.
Neurologists, pediatric neurologists, epileptologists, developmental neuroscientists, medical geneticists, and developmental biologists.
Primary mechanisms.How does glucose generate oxidative stress in Peripheral Nerve? Irina Obrosova.Glycation in Diabetic Neuropathy: Characteristics, Consequences, Causes and Therapeutic Options, Paul Thornalley.Secondary changes.Protein Kinase C Changes in Diabetes -- Is the concept relevant to neuropathy? Joseph Eichberg.Are MAP kinases glucose transducers for diabetic neuropathies? Tertia D. Purves and David R. Tomlinson. Neurofilaments in Diabetic Neuropathy, Paul Fernyhough and Robert E. Schmidt.Apoptosis in Diabetic Neuropathy, Aviva Tolkovsky.Nerve and Ganglion Blood Flow in Diabetes: An Appraisal, Douglas W. Zochodne.Manifestations.Potential Mechanisms of Neuropathic Pain in Diabetes Nigel A. Calcutt.Changes in nerve conduction velocity - What Are Their Mechanisms and What Do They Mean? Joe Arezzo.Neuropathology and Pathogenesis of Diabetic Autonomic Neuropathy, Robert E. Schmidt.The Role of the Schwann Cell in Diabetic Neuropathy, Luke Eckersley.Potential Treatment.The Polyol Pathway and Diabetic Peripheral Neuropathy, Peter J. Oates.Nerve Growth Factor for the Treatment of Diabetic Neuropathy: What went wrong, What went right and what does the future hold? Stuart C. Apfel.ACE Inhibitors -- Are there Credible Mechanisms for Beneficial Effects in Diabetic Neuropathy? Rayaz Malik and David Tomlinson.Clinical trials for drugs against diabetic neuropathy -- can we combine scientific needs with clinical and economic practicalities? Dan Ziegler and Dieter Luft.
- Edition: 1
- Latest edition
- Volume: 50
- Published: August 5, 2002
- Language: English
DT
David Tomlinson
Affiliations and expertise
University of Manchester, United KingdomRB
Ronald J. Bradley
Affiliations and expertise
Louisiana State University Medical Center, School of Medicine, Baton Rouge, U.S.A.RH
R. Adron Harris
Affiliations and expertise
University of Texas, Austin, USAPJ
Peter Jenner
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.
Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.
Affiliations and expertise
Emeritus Professor of Pharmacology, Institute of Pharmaceutical Sciences, King’s College London, London, UKRead Neurobiology of Diabetic Neuropathy on ScienceDirect